Abstract
Immune-modifying therapy is the mainstay of treatment for moderate to severe inflammatory bowel disease (IBD) and is associated with an increased risk of infections.1, 2 A recent study found that compared with non-IBD subjects, patients with inflammatory bowel disease are at an increased risk of influenza infection.3 Vaccination against influenza is recommended in patients with IBD by several professional society guidelines and is included as a health care quality measure by the American Gastroenterology Association and Crohn’s and Colitis Foundation.4–6 However, certain immunosuppressive therapies, specifically immunomodulators and/or combinations of biologics with immunomodulators, may impact the generation of protective immune responses after influenza vaccination. Attempts to improve...

This publication has 23 references indexed in Scilit: